Seon Y. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

Journal: Scientific reports
Published: April 19, 2021

Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer.

Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer.

Journal: Targeted oncology
Published: April 15, 2020

Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4.

Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4.

Journal: Cancer letters
Published: October 31, 2019

Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.

Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.

Journal: Experimental & molecular medicine
Published: February 12, 2019

Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.

Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.

Journal: Targeted oncology
Published: May 14, 2018

Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation.

Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation.

Journal: Cancer research
Published: January 11, 2018

Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement.

Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement.

Journal: Oncotarget
Published: February 08, 2017

Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Journal: Oncotarget
Published: December 07, 2015

AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.

AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.

Journal: Anticancer research
Published: March 10, 2015

AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.

AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.

Journal: PloS one
Published: August 26, 2014

MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.

MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.

Journal: Cancer research
Published: October 30, 2013

Neuroendocrine differentiation in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor.

Neuroendocrine differentiation in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor.

Journal: Tuberculosis and respiratory diseases
Published: May 06, 2013
Showing 1-12 of 12

Last Updated: 09/26/2026